IL325291A - חלבונים קושרי-אנטיגן אנטי- trailr2ושימושים בהם - Google Patents

חלבונים קושרי-אנטיגן אנטי- trailr2ושימושים בהם

Info

Publication number
IL325291A
IL325291A IL325291A IL32529125A IL325291A IL 325291 A IL325291 A IL 325291A IL 325291 A IL325291 A IL 325291A IL 32529125 A IL32529125 A IL 32529125A IL 325291 A IL325291 A IL 325291A
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
cdr3
cdr1
Prior art date
Application number
IL325291A
Other languages
English (en)
Original Assignee
Odyssey Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odyssey Therapeutics Inc filed Critical Odyssey Therapeutics Inc
Publication of IL325291A publication Critical patent/IL325291A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL325291A 2023-06-29 2024-06-28 חלבונים קושרי-אנטיגן אנטי- trailr2ושימושים בהם IL325291A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363524095P 2023-06-29 2023-06-29
PCT/US2024/035969 WO2025006846A2 (en) 2023-06-29 2024-06-28 Anti-trailr2 antigen-binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
IL325291A true IL325291A (he) 2026-02-01

Family

ID=91961924

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325291A IL325291A (he) 2023-06-29 2024-06-28 חלבונים קושרי-אנטיגן אנטי- trailr2ושימושים בהם

Country Status (8)

Country Link
KR (1) KR20260032566A (he)
CN (1) CN121532423A (he)
AR (1) AR133108A1 (he)
AU (1) AU2024308381A1 (he)
IL (1) IL325291A (he)
MX (1) MX2025015221A (he)
TW (1) TW202515917A (he)
WO (1) WO2025006846A2 (he)

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CN101925612A (zh) 2007-11-27 2010-12-22 维文蒂阿生物技术公司 针对癌相关的nfkbib变体的表位的抗体及其用途
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
CN106046168A (zh) 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
SG2014010482A (en) 2011-08-17 2014-04-28 Glaxo Group Ltd Modified proteins and peptides
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
PL3248986T3 (pl) 2014-05-16 2022-05-16 Ablynx Nv Domeny zmienne immunoglobuliny
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
EP3271391A1 (en) 2015-03-20 2018-01-24 Ablynx N.V. Glycosylated immunoglobulin single variable domains
NZ777930A (en) * 2015-07-16 2025-05-02 Inhibrx Biosciences Inc Multivalent and multispecific dr5-binding fusion proteins
CN115925919A (zh) 2015-11-13 2023-04-07 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
CN120535622A (zh) 2015-11-18 2025-08-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
SG10202108972RA (en) 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
HRP20241501T1 (hr) 2017-01-17 2025-01-03 Ablynx Nv Poboljšana veziva albumina u serumu
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
WO2020047705A1 (zh) * 2018-09-03 2020-03-12 安菲尼生命科技有限公司 Dr5单域抗体及其用途
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions

Also Published As

Publication number Publication date
KR20260032566A (ko) 2026-03-09
AR133108A1 (es) 2025-08-27
CN121532423A (zh) 2026-02-13
AU2024308381A1 (en) 2025-11-20
WO2025006846A2 (en) 2025-01-02
WO2025006846A8 (en) 2025-05-01
WO2025006846A3 (en) 2025-03-06
TW202515917A (zh) 2025-04-16
MX2025015221A (es) 2026-02-03

Similar Documents

Publication Publication Date Title
AU2020329466B2 (en) Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
CA2764392C (en) Tetravalent bispecific antigen binding proteins
KR102098919B1 (ko) 이중 특이성 단백질 및 이의 제조 방법
CN101495510B (zh) 单链fc多肽
AU2019326635B2 (en) Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof
JP2013515508A5 (he)
JP2009240323A5 (he)
CA2972604A1 (en) Anti-cd47 antibodies and uses thereof
CN102264390A (zh) Il6免疫治疗
RS66208B1 (sr) Pd-1-vezujući molekuli i metode njihove upotrebe
KR20160138103A (ko) 다중특이적 항체
CA2761233A1 (en) Tri- or tetraspecific antibodies
AU2014214530A1 (en) IL-11R binding proteins and uses thereof
US20240043566A1 (en) Bi-functional molecules
JPWO2021030657A5 (he)
CA3227854A1 (en) Novel anti-sirpa antibodies
WO2020192709A1 (en) Novel bispecific polypeptide complexes
US20210115138A1 (en) Novel bispecific pd-1/lag-3 antibody molecules
IL325291A (he) חלבונים קושרי-אנטיגן אנטי- trailr2ושימושים בהם
CA3229430A1 (en) Anti-vegfr1 antibodies and their uses
JPWO2022047243A5 (he)
US20250282874A1 (en) Bifunctional protein, and preparation thereof and use thereof
WO2026041038A1 (en) Novel anti-cdh6 antibodies and uses thereof
WO2022156670A1 (en) Multispecific antibodies against sars-cov-2 and methods of use thereof
JP2024541982A (ja) 新規の抗ｉｌ－３６ｒ抗体